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Abstract 
Acute kidney injury (AKI) is now recognized as a heterogeneous syndrome that not only affects acute morbidity and 
mortality, but also a patient’s long-term prognosis. In this narrative review, an update on various aspects of AKI in criti-
cally ill patients will be provided. Focus will be on prediction and early detection of AKI (e.g., the role of biomarkers to 
identify high-risk patients and the use of machine learning to predict AKI), aspects of pathophysiology and progress 
in the recognition of different phenotypes of AKI, as well as an update on nephrotoxicity and organ cross-talk. In addi-
tion, prevention of AKI (focusing on fluid management, kidney perfusion pressure, and the choice of vasopressor) and 
supportive treatment of AKI is discussed. Finally, post-AKI risk of long-term sequelae including incident or progression 
of chronic kidney disease, cardiovascular events and mortality, will be addressed.
Keywords: Acute kidney injury, Diagnosis, Biomarkers, Machine learning, Heterogeneity, Phenotypes, 
Pathophysiology, Nephrotoxicity, Organ cross-talk, Fluid therapy, Blood pressure management, Vasopressor, Long-
term consequences
Introduction
The availability of a consensus definition of acute kidney 
injury (AKI) [1] has been an important step in establish-
ing AKI epidemiology. AKI affects 30–60% of critically ill 
patients and is associated with acute morbidity and mor-
tality [2]. Evidence is also accumulating that the burden 
of AKI extends beyond the acute phase with progres-
sion to chronic kidney disease (CKD), increased risk of 
cardiovascular complications, recurrent episodes of AKI 
and long-term mortality [3]. Prevention of development 
and/or progression is currently limited to hemodynamic 
and fluid status optimization and avoidance of nephro-
toxins. Search for a specific pharmacologic treatment 
is hampered by the late diagnosis and the complex and 
incompletely elucidated pathophysiology. Progress in the 
management of AKI is to be expected from the recog-
nition that AKI is a very heterogeneous syndrome with 
variable etiology, pathophysiology and clinical presenta-
tion [4].
In this narrative review, we discuss methods for early 
diagnosis of AKI, clinical phenotypes, pathophysiology, 
nephrotoxicity, optimal supportive management, as well 
as the importance of recovery and long-term follow-up. 
A discussion of renal replacement therapy (RRT) is out-
side the scope of this review.
Towards an improved AKI diagnosis?
Although the kidney has many functions, AKI is mostly 
defined as a decrease of glomerular filtration rate (GFR). 
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The KDIGO workgroup proposed a consensus defini-
tion and staging system for clinical practice (the KDIGO 
definition) that relies on the increase of serum creati-
nine (Scr) within 7 days and/or the presence of oliguria 
(Fig. 1), both surrogate markers of GFR [1]. This defini-
tion has enabled to streamline research in the field. How-
ever, both Scr and urine output may also be influenced 
by non-renal and non-GFR-related factors and are, 
therefore, imperfect markers of reduced GFR [5]. Conse-
quently, the diagnosis of AKI by KDIGO criteria should 
be interpreted in the clinical context. Controversy on 
how to determine baseline kidney function is another 
drawback of the consensus definition. Despite the con-
cerns about oliguria as a marker of kidney function, there 
is evidence that oliguria identifies patients with worse 
outcomes [6, 7]. In addition, because of the long half-life 
of creatinine and the presence of renal functional reserve 
(renal reserve capacity that can be recruited before basal 
GFR starts to decline [8]), Scr requires time to accurately 
reflect GFR resulting in delayed recognition of kidney 
dysfunction. Potential solutions for a more timely detec-
tion of a reduced GFR could be measurement of creati-
nine clearance over 2 or 4  h, kinetic eGFR calculated 
from two serial creatinine measurements [9], or utiliz-
ing the plasma disappearance of an injected compound 
like iohexol that is dependent on renal clearance. These 
methods have not been extensively investigated or used 
in the ICU setting. Bedside real-time GFR measurements 
using injection of a dye and fluorescent probes and ena-
bling earlier diagnosis of kidney dysfunction are under 
investigation, but do not yet have regulatory approval 
[10]. Cystatin-C, another marker of glomerular filtration, 
might be useful in settings of muscle wasting, but is also 
affected by comorbidity.
Late AKI diagnosis has been implicated for the lack of 
efficacy success in drug trials. This explains the interest 
in biomarkers to predict KDIGO AKI (with 1700 publica-
tions over the past 5 years). Ideally, increased biomarker 
levels indicate kidney injury before the KDIGO criteria 
for AKI are met (so-called “subclinical AKI”), and thus 
might trigger early diagnostic and preventive measures 
[11]. The most widely investigated markers are neu-
trophil gelatinase-associated lipocalin (NGAL), kidney 
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Fig. 1 Different phases of AKI development and progression and associated diagnostic tests. AKI acute kidney injury, TIMP tissue inhibitor of metal-
loproteinases, IGFBP  insulin-like growth factor-binding protein, NGAL  neutrophil gelatinase-associated lipocalin, UO urine output
injury molecule -1 (KIM-1), liver fatty acid binding pro-
tein (LFABP) and the product of and tissue inhibitor of 
metalloproteinase 2 and insulin-like growth factor-bind-
ing protein 7 (TIMP-2*IGFBP7; Nephrocheck™) (Fig. 1) 
(Table 1). Only NGAL and TIMP-2*IGFBP7 are available 
for clinical use. TIMP-2*IGFBP7 is a urinary marker of 
cell cycle arrest, reflecting cellular stress that precedes 
tissue damage (Fig.  1). It has FDA and EMEA approval 
for the prediction of AKI stage 2 and 3 within 12 h in crit-
ically ill patients with cardiac and respiratory failure [12]. 
High sensitivity (> 0.3) and high specificity (> 2.0) cutoffs 
have been defined, allowing risk stratification [13]. Two 
recent meta-analyses showed an AUROC 0.83 for the 
prediction of AKI within 24 h in cardiac surgery [14] and 
0.74 for the prediction of stage 2 and 3 within 12 h in the 
critically ill [15]. A meta-analysis on the accuracy of uri-
nary NGAL showed an AUROC of 0.75 for severe AKI 
with cut-offs of 12 ng/ml for 95% sensitivity and 580 ng/
ml for 95% specificity [16]. Significant heterogeneity is, 
however, reported related to the study population (pre-
test probability), timing of sampling, prediction window 
and severity of predicted AKI. It should also be acknowl-
edged that the gold standard definition (KDIGO criteria) 
refers to kidney function, not damage. “False positives” 
may reflect “subclinical” injury and false negatives may 
reflect “hemodynamic” (previously called prerenal) AKI. 
Combining damage biomarkers with the functional 
KDIGO criteria may allow better characterization of AKI 
Table 1 Overview of current AKI biomarkers and tests; mechanisms and clinical applications
Biomarker/functional test Mechanism Clinical application Comment References
Biomarkers and tests that are available for clinical use
Blood
 Cystatin-C Glomerular filtration Earlier detection of AKI, not 




 Proenkephalin (PenKid ®) Glomerular filtration Earlier detection of AKI Scr alternative [146]
 NGAL Tubular damage Earlier detection of AKI Also increased in other condi-




 TIMP-2 × IGFBP7 (Nephro-
Check ®)
Cellular stress tubules (cell cycle 
arrest)
Earlier detection AKI stage 2 or 3 
within 12-h
High sensitivity cutoff > 0.3
High specificity cutoff > 2.0
[12–14]
 NGAL Tubular damage Earlier detection AKI Cutoff unclear [16, 147, 148]
 KIM-1 Proximal tubular damage Earlier prediction of AKI FDA recommends its use for 
assessment of drug toxicity
[149]
 Cystatin-C Tubular function Earlier detection kidney injury Limited evidence [150]
Functional tests
 Furosemide stress test Tubular function Prediction of AKI progression Cutoff urine output > 200 mL 
per 2 h
[41, 42]
 Renal Resistive Index (duplex 
ultrasound)
Kidney circulation Prediction of AKI persistence Controversial evidence [34]
 Loss of RFR Loss of renal functional reserve Prediction of AKI in cardiac 
surgery
Marker of incomplete recovery
Cumbersome, predominantly 
used in research setting
[19, 20]
Tests not available for clinical use worldwide
Blood
 SuPAR Cellular bioenergetics and 
oxidative stress
Pre-exposure risk factor Limited evidence [55, 151]
Urine
 IL-18 Inflammation, early detection 
AKI
Low predictive power for AKI [152]
 LFABP Proximal tubular damage Prediction of AKI Available for clinical use in Japan [153]
 CHI3L1 Stress or damage tubules and 
macrophage activation
Prediction of AKI Alternative name YKL-40
Limited evidence
[154, 155]
 DKK-3 Fibrosis Preop DKK-3 predicts postop AKI 
and predicts long-term kidney 
function
Limited evidence [56]
 CCL14 Fibrosis AKI persistence Limited evidence [39]
phenotypes and improve the diagnostic accuracy [11]. 
Incorporation of biomarkers in the AKI definition has, 
therefore, been suggested [11].
Despite extensive research, guidance on how AKI bio-
markers should be used in clinical practice is lacking. 
Currently, these biomarkers have been successful in iden-
tifying high-risk patients for clinical trials investigating 
early prevention strategies [17, 18]. Demonstration of 
utility/effectiveness in a real-world setting would, how-
ever, require a comparison of two strategies where clini-
cians have or do not have access to the biomarker result. 
Costs, availability, and the paucity of therapeutic options 
are other barriers to widespread clinical use.
Another recently proposed AKI predictor is loss of 
renal functional reserve (measured with a high oral pro-
tein load), that has shown to predict postoperative AKI in 
cardiac surgery [19] and might be a marker of incomplete 
recovery [20]. However, this clinical utilization of this 
parameter also remains to be evaluated.
Electronic alerts (e-alerts) have been suggested as solu-
tions for early diagnosis of AKI [21]. They are based on 
prevalent KDIGO criteria and their main advantage is to 
be expected in the less monitored non-ICU setting and 
only when linked to an order set and/or action [22]. The 
evidence for benefit in the ICU is limited [23].
More promising are prediction models either based on 
logistic regression or machine-learning methodologies 
taking advantage of the large amount of data available in 
electronic health records (EHR). The past years have seen 
a proliferation of AKI prediction models based on artifi-
cial intelligence [24, 25]. Only a few have focused on ICU 
patients (Table 2). Most models have been developed ret-
rospectively in a preprocessed dataset (research dataset 
or electronic health records) and only use the creatinine 
criteria. They show fair to excellent accuracy (AUC 0.75–
0.90) and good calibration. Accuracy is generally higher 
with a shorter prediction window (lead time) and more 
severe AKI. These models either provide snap-shot scores 
[26], moving windows [27] or continuous AKI prediction 
[28]. Only one of these ICU models has undergone exter-
nal validation confirming good accuracy in a multicenter 
independent dataset [29]. The last step in the validation 
process of these prediction models, that still has to be 
taken, is translation into a bedside real-time prediction 
tool (using the “uncleaned” EHR) providing continu-
ously updated AKI probability with uncertainty levels. 
This model should then be evaluated in RCT’s testing 
the impact of its use on patient-centered outcomes when 
integrated in the real-world clinical workflow, eventu-
ally linked to a clinical decision support system (“turning 
predictions into action”). Such a trial is currently ongoing 
(NCT03590028) (Table 3).
Clinical phenotypes
Over the past decade, it is increasingly recognized that 
AKI is a heterogeneous syndrome not only with regard 
to exposure (low cardiac output, sepsis, major surgery, 
toxicity, etc.) and pathophysiology (hypoperfusion, 
Table 2 Summarizing the characteristics of available machine‑learning models for AKI prediction in the ICU
HER electronic health record
* Only ICU results are given
Flechet [26] Koyner [27] Churpek [29] Chiofolo [28]
Database Research database EHR EHR EHR
% in ICU 100 21 19 100
Methodology Random forest Gradient boost Random forest
N development 2123 72,695 4572
N validation 2367 48,463 495,971 1958
Validation type Matched held-out set 40% held-out set 40% held-out set
N variables 97 59 ?
Timing Model 1: baseline
Model 2: admission
Model 3: day 1
Model 4: d1 + hemodynamics
Moving 12 h windows Continuous real-time




18% any AKI 30% any AKI
14% stage 2–3




Stage 1 48 h: 0.73
Stage 2 48 h: 0.85
RRT 24 h: 0.95
Stage 2 48 h: 0.87 Any AKI: 0.882
Stage 2–3: 0.878
Variable importance plot No Yes Yes No
Note Available on website AKI-predictor Validation [27]
inflammation, etc.) but also with regard to the clini-
cal presentation (severity and evolution). A potential 
approach to distinguishing clinical phenotypes is the 
application of latent class analysis to a set of clinical and 
biological variables to define subgroups with different 
outcomes and treatment responses [30, 31]. The prognos-
tic importance of AKI duration and recovery pattern has 
been demonstrated in several analyses. A recent ADQI 
conference defined transient AKI and persistent AKI 
based on duration of more or less than 48  h [32]. Pre-
dicting the course of AKI could enable to define different 
phenotypes requiring different management. Traditional 
urinary biochemistry [33] and renal resistive index [34] 
perform poorly in this regard, especially in sepsis. Bio-
markers may be helpful [35, 36] although results are not 
uniformly positive [37, 38]. A new biomarker, urinary 
C–C motif chemokine ligand-14 (CCL14) has recently 
been identified as a very accurate predictor (outperform-
ing all other biomarkers) of persistent AKI stage 3 in 
ICU patients with severe AKI [39]. Limited data suggest 
that kinetic eGFR better predicts AKI progression better 
than some biomarkers [40] and the same applies to the 
furosemide stress test (FST) that performed better than 
biochemical biomarkers in predicting the progression to 
AKI stage 3 [41, 42]. Future developments in measuring 
real-time GFR or using real-time AKI prediction models 
will certainly contribute to this field.
Acute kidney disease: a recent entity
Acute kidney disease (AKD) defined as an AKI episode 
that lasts longer than 7  days but less than 90  days has 
recently been proposed as a concept (Fig. 1) [32]. It aims 
at closing the gap between AKI and CKD (which requires 
3 months to be diagnosed). AKD uses the creatinine cri-
teria of the KDIGO definition. It is important to note 
that the diagnosis of AKD (severity) or apparent recovery 
may be affected by the decrease of Scr related to muscle 
mass loss associated with chronic critical illness [5]. The 
relationship between persistent AKI, AKD and CKD as 
well as interventions that may interfere with this evolu-
tion require further study (Fig. 2).
Pathophysiology of a heterogeneous syndrome
The pathophysiology of AKI has been insufficiently elu-
cidated not in the least because kidneys are complex and 
rather inaccessible organs. Animal models poorly reflect 
human pathophysiology (where comorbidities play an 
important role) and the AKI syndrome is heterogenous 
[43], illustrated by recent studies demonstrating different 
genomic responses in volume depletion, ischemic and 
septic animal models of AKI [44, 45]. In clinical practice, 
it is likely that there are distinct, but overlapping patho-
physiological paradigms of AKI that may require indi-
vidualized treatments [4], explaining in part the failure 
of many interventions in clinical trials. With the excep-
tion of specific intrinsic renal disease, AKI pathology can 
range from decreased GFR, mediated purely by systemic 
or local hemodynamic alterations through reversible 
tubular stress/injury to frank tubular necrosis. Histo-
logic changes in AKI of critical illness are generally focal 
and modest [46]. Within this complex pathophysiology, 
a number of common themes emerge with patterns of 
inflammatory, ischemic and nephrotoxic kidney injury 
that can occur sequentially and concomitantly and may 
be differently influenced by underlying diseases (Fig. 3).
Identification of clinical phenotypes with different 
pathophysiology and outcome is essential to identify 
new therapeutic targets [4]. The importance of clini-
cal context is illustrated in cardiorenal syndrome due to 
acute decompensation of chronic heart failure, where 
renal congestion is the predominant driver of worsening 
kidney function. Although successful resolution of fluid 
overload with diuretics or ultrafiltration may induce an 
increase of Scr, it is, however, associated with improved 
longer term kidney function [47], even in patients with 
elevated renal injury markers [48]. This suggests that the 
benefit of decongestion outweigh the modest increase 
Table 3 Suggestions for future AKI research
RCT evaluating the impact of real-time prediction models on AKI management and outcome
RCT comparing biomarker levels versus not revealing them on clinical outcomes
RCT comparing higher MAP target with usual care on AKI incidence in patients with pre-existing hypertension
Evaluation of MAP targets to prevent AKI after cardiac arrest
Decongestion in patients with AKI and fluid overload: comparison between diuretics and mechanical fluid removal
Long-term renal function in COVID-19 survivors with AKI
Impact of RAAS blockade on the long-term outcomes following AKI
Controlled studies on clinical effects of longer term nephrology follow-up
Prospective evaluation of the association between persistent AKI—AKD—CKD
of Scr and, for instance, that NT-proBNP might be a 
more useful prognostic biomarker than markers of kid-
ney damage in this specific setting [49]. It is important 
to note, however, that often numerous AKI risk factors 
and clinical settings co-exist or follow sequentially so 
that clear clinical inferences are difficult to draw, which 
emphasizes the importance of further research to iden-
tify underlying dominant AKI phenotypes to guide thera-
peutic intervention.
The interplay of different pathophysiological pathways 
is most pronounced in sepsis, the most common cause of 
AKI in the critically ill [2]. Generally, the ischemic com-
ponent does not appear to result from reduced global 
kidney blood flow. Instead, periglomerular shunting may 
reduce glomerular blood flow and inflammation-induced 
endothelial dysfunction induces microvascular distur-
bances and microthrombi formation [50, 51]. Afferent 
vasoconstriction due to tubulo-glomerular feedback is 
considered a consequence rather than a cause of tubular 
dysfunction [51]. The inflammatory component results 
from damage-associated molecular patterns (DAMPs) 
and pathogen-associated molecular patterns (PAMPs) 
that are present in the peritubular capillaries and 
undergo glomerular filtration and subsequently inter-
act with Toll-like receptors located on the brush border 
membrane of epithelial cells in the proximal tubule [50, 
51]. Recruitment of immune cells further contributes to 
an immuno-pathophysiological response and immune-
mediated damage [52]. Besides inflammatory damage, 
recent experimental data have suggested that cell cycle 
arrest, deficient autophagy, ferroptosis, mitochondrial 
dysfunction and metabolic reprogramming are mecha-
nisms that contribute to tubular dysfunction in septic 
AKI [50].
Some of these pathways have already resulted in explo-
ration of potential interventions in patients. The kidney 
being a highly metabolically active organ, one of the path-
ways that recently received significant attention is mito-
chondrial dysfunction and impaired energy metabolism 
due to deficiency of nicotinamide adenine dinucleotide 
(NAD+) and metabolic reprogramming [50, 51]. Exper-
imental AKI is characterized by deficiency of PPAR-
gamma-coactivator 1a (PGC-1a), a critical regulator of 
mitochondrial biogenesis. Deficiency of PGC-1a is linked 
to impaired synthesis of NAD+, an essential player in 
cellular energy metabolism (mainly fatty acid oxida-
tion and glycolysis). Markers of decreased NAD+ have 
been demonstrated in patients developing AKI after 
cardiac surgery. In addition, nicotinamide, a precur-
sor of NAD+ reduced postoperative creatinine levels 
in a phase I RCT [53]. A larger RCT is currently ongo-
ing (NCT04342975). Metabolic reprogramming refers 
to a switch from oxidative phosphorylation to less effi-
cient energy production through glycolysis in response 
Time (days)
AKI CKD





Day 7Day 0 Day 90
Recovery Recovery Recovery« Normal »
Kidney
Potenal opportunies for treatment
Prevenon of  AKI recurrence 
Prevenon of transion to CKD
RAAS inhibitors
Selecve mineralocorcoid receptor antagonists?
Sodium-glucose co-transporter-2 inhibitors ?
Fig. 2 Following the development of AKI, several scenarios are possible that may lead to recovery of renal function or to more prolonged dysfunc-
tion. Acute kidney disease (AKD) is assessed between 7 and 90 days after AKI. In patients that do not improve, chronic kidney disease (CKD) is estab-
lished after day 90. Biomarkers of renal injury and function may be able to refine the prediction of rapid recovery (i.e., transient AKI) or transition to 
more persistent impairment of renal function and several therapeutic interventions may be able to modulate the progression of the disease course
to decreased oxygen and substrate supply. It decreases 
the production of reactive oxygen species (ROS) and is 
a survival mechanism with reduction of non-vital func-
tions paying the price for maintaining cellular integrity, 
which could explain the dissociation between structure 
and function that characterizes AKI. However, switch-
back to oxidative phosphorylation (mediated by AMPK) 
appears necessary for survival but requires restoration of 
functional mitochondria by mitophagy and mitochon-
drial biogenesis [50, 51].
Biomarkers have contributed to unravelling the patho-
physiology of AKI. Besides metabolic reprogramming, 
cell cycle arrest is another protective mechanism that 
prevents cells with DNA damage from dividing and 
downregulates energy expenditure. However, as with 
metabolic reprogramming, it appears to be a double edge 
sword because with persistent cell cycle arrest repair 
becomes maladaptive resulting in AKI to CKD transi-
tion [54]. Chemokine C–C motif ligand-14 (CCL14) 
was recently described as a marker of AKI persistence. 
The hypothesized mechanism (and potential therapeu-
tic target) is CCL14 release by tubular cells in response 
to inflammatory mediators, triggering infiltration and 
differentiation of monocytes and T cell-mediating fibro-
sis and incomplete kidney recovery [39]. Soluble uroki-
nase plasminogen activator receptor (suPAR), a marker 
of chronic inflammation and immune activation is 
increased in a number of exposures including increas-
ing age, diabetes, cardiovascular disease, infection and 
smoking. It also predicts incident CKD and CKD pro-
gression. Admission levels independently predicted 
development of AKI within the first 7  day after various 
procedures [55]. Importantly, targeting suPAR oxidative 
pathways appears to attenuate damage in experimental 
AKI [55] suggesting potential as therapeutic target. Simi-
larly, urinary Dickkopf-3 (DKK3) is a pro-fibrotic gly-
coprotein secreted by renal tubular cells that modulates 
the Wnt/b pathway involved in tubulo-interstitial fibrosis 
Fig. 3 Simplified overview of AKI pathophysiology illustrating the heterogeneity in etiology, presentation, pathology, progression and outcomes 
and how investigations may help us understand underlying AKI phenotypes at various stages in illness. Green indicates functional/reversible 
processes; red indicates acute and chronic tissue injury. Yellow boxes indicate etiological factors in AKI pathogenesis, blue boxes diagnostic tests 
indicative of underlying pathophysiological processes
and predicts GFR loss and renal fibrosis in CKD. It has 
recently been described as a strong pre-operative predic-
tor of AKI post-cardiac surgery and, importantly, wors-
ening of long-term renal function after AKI [56]. These 
findings emphasize the interconnected pathophysiology 
of AKI episodes and CKD progression. The previously 
mentioned study using latent class analysis for detec-
tion of clinical phenotypes found two sub-phenotypes 
(AKI-SP1 and AKI-SP2) with different biomarker pro-
files (markers of endothelial dysfunction such as tumor 
necrosis factor receptor-1, angiopoietin-1 and 2), kid-
ney and patient outcome and response to treatment with 
vasopressin [57], apparently genetically determined [58]. 
These are only the first steps in the search for pathophysi-
ological pathways that could lead to precision medicine 
and clinical benefit.
What is new in nephrotoxicity?
There are drugs that are directly nephrotoxic, drugs that 
are not nephrotoxic but interfere with intrarenal hemo-
dynamics (i.e., ACE-inhibitors, NSAIDs) and drugs that 
are not nephrotoxic, but accumulate in renal failure and 
should, therefore, also be prescribed with caution. The 
most commonly incriminated drugs are contrast agents 
and antibiotics but multidrug toxicity maybe the pre-
dominant problem. When prescribing drugs, clinicians 
should consider how they affect kidney function and 
whether their clearance is affected by the presence of 
AKI. Prescription of nephrotoxic medications should be 
minimized in terms of frequency and duration, however, 
they should not be withheld in life-threatening situations 
owing to concern for AKI [59]. Drugs with potentially 
renoprotective effects should be continued even if they 
are associated with a mild rise in serum creatinine (i.e., 
ACE-inhibitors in diabetic nephropathy).
Historically, contrast agents have been considered an 
important cause of AKI. However, recent observational 
studies with propensity score-adjusted models found 
no relevant difference in AKI incidence between those 
exposed or not exposed to modern contrast agents, 
even in septic and ICU patients [60–62], suggesting that 
the risk of contrast-induced AKI (causal association) is 
much lower than previously thought and that contrast-
associated AKI (temporal association) frequently has 
other causes. The absence of a post-contrast increase of 
biomarkers of kidney injury [63] supports this concept. 
Hence, contrast-enhanced CT scan should not be post-
poned if required for the diagnosis of a life-threatening 
condition. In all other situations, the uncertain risk of 
contrast-induced AKI should be balanced against the risk 
of missing an important diagnosis, taking into account 
the possibility of alternative imaging procedures [64]. 
Recent guidelines suggest using moderate contrast doses 
and prophylactic isotonic hydration in patients at risk 
[65] although even the latter has been questioned [66]. 
It is evident that in critically ill patients hydration should 
account for the volume status of the individual patient, 
balancing the risk of kidney hypoperfusion against the 
risk of fluid overload. A large RCT confirmed that acetyl-
cysteine has no benefit and that bicarbonate is not better 
than saline in preventing contrast nephropathy [67].
With regard to dosing of antibiotics, recent literature 
mainly stresses the danger of subtherapeutic concen-
trations in the treatment of multidrug-resistant (MDR) 
microorganisms, which makes dosing challenging for 
antibiotics with narrow therapeutic index such as vanco-
mycin, aminoglycosides and polymyxins. Trials are ongo-
ing to investigate optimal administration and duration of 
antibiotics. (https:// warwi ck. ac. uk/ fac/ sci/ med/ resea rch/ 
ctu/ trials/ adapt sepsis and ClinicalTrials.gov Identifier: 
NCT03213990).
The nephrotoxicity of vancomycin has been debated 
over many years and is probably lower than previously 
suggested [68]. A recent meta-analysis showed that the 
incidence of AKI increases with higher trough concen-
trations and is significantly higher for trough concen-
trations ≥ 20  μg/mL. It also suggested that AUC/MIC 
monitoring strategy (aiming at a target of 400) could 
result in less nephrotoxicity [69]. In patients at high 
risk or with early signs of kidney dysfunction, a switch 
to a less toxic alternative should be considered. Several 
observational trials showed increased nephrotoxic-
ity when vancomycin was combined with piperacillin/
tazobactam in comparison with vancomycin alone or in 
combination with other beta-lactams [70]. Others sug-
gested that the Scr increase does not reflect true AKI (a 
decrease of GFR), but an inhibition of tubular secretion 
of creatinine by piperacillin/tazobactam but this may be 
valid only for lower stages of AKI [71]. Future RCTs with 
non-creatinine markers of GFR should clarify the issue. 
The emergence of difficult-to-treat MDR gram-negative 
bacteria has resulted in renewed interest in polymyxins 
and aminoglycosides, mainly amikacin. Most recent trials 
on amikacin focus on optimal dosing with regard to effi-
cacy, whereas nephrotoxicity has been poorly studied in 
ICU patients. A small propensity-based study suggested 
no toxicity with short (< 3  days) amikacin treatment, 
which might be sufficient to bridge the waiting time for 
bacteriological results [72]. Polymyxins are nephrotoxic 
[73] with colistin being more harmful than polymyxin B 
[74]. However, since they are mostly used as a last resort, 
kidney dysfunction is often an unavoidable side effect. A 
combination of injury biomarkers and therapeutic drug 
monitoring could help to reduce nephrotoxicity, although 
evidence from clinical studies is lacking.
Organ cross‑talk
During the development and presence of AKI in the 
critically ill, virtually all non-renal organs are affected. 
This generalized systemic process could be representing 
the impact of the underlying disease (shock, systemic 
inflammation) on multiple organ systems. However, 
an alternative explanation suggests mutual impact of 
failing organs, known as organ cross-talk could also 
play a role. AKI can indeed result from failure of other 
organs, most well-known examples being cardiorenal 
syndrome, from a failing heart, and hepatorenal syn-
drome, from a failing liver. There are also indications 
that ARDS and (the modality of ) mechanical venti-
lation may affect kidney function [75]. However, the 
concept of cross-talk also works in the other direction 
and considers AKI as a systemic disease with impact on 
other organs such as the heart [76], lung [75], liver and 
brain [77, 78]. Instead of being an innocent bystander in 
the process of multiple organ failure, the kidneys may 
indeed initiate metabolic or humoral pathways affect-
ing distant organ function. Potential mechanisms are 
the consequences of decreased kidney function, lead-
ing to accumulation of uremic toxins, fluid overload, 
electrolyte disturbances and acid–base dysbalance. 
Alternatively, an inflammatory mechanism involv-
ing neutrophil migration and inflammatory mediators 
originating in the kidney or side effects of supportive 
treatment with renal replacement therapy (RRT) may 
play a role. Cross-talk also exists between the kidney 
and the immune system with inflammation as being an 
important pathophysiological mechanism of AKI on 
the one hand and AKI-induced immunosuppression 
resulting in a higher susceptibility to develop secondary 
infections on the other hand. The uremic toxin resis-
tin appears to be an important mediator of impaired 
cellular immunity [79]. The clinical relevance of AKI-
induced immune paralysis is illustrated by the obser-
vation that renal dysfunction increases the chances of 
developing serious infections following heart surgery 
[80] and approximately half of the patients with AKI 
who do not survive, die of sepsis [81, 82].
Direct evidence for an impact of AKI on other organs 
mostly results from animal experiments (summarized 
in [77, 78]) since the impact of a common etiology and 
organ cross-talk is difficult to discern in the clinical situ-
ation. For instance, a galectin-3-dependent pathway has 
been shown to be involved in the reno-cardiac syndrome 
[83]. Recent animal studies also suggest that acute renal 
ischemia may induce both functional and transcriptional 
changes in the lung, independent of uremia, but related 
to leukocyte trafficking [84].
Clearly, cross-talk between the kidney and other 
organs may be an important contributor to the increased 
morbidity and mortality that is associated with AKI [85] 
and may explain why, as compared to matched controls, 
patients with AKI are more likely to die from sepsis, 
bleeding, delirium and respiratory failure [75, 76, 86].
Prevention of AKI
General principles
General preventive measures should be applied to all 
patients admitted to the ICU, including correction of 
hypovolemia and hypotension, discontinuation and 
avoidance of nephrotoxic agents and correction of hyper-
glycemia [64].
Fluid management
The aim of fluid administration is to correct intravascular 
hypovolemia without causing fluid overload and associ-
ated complications, including new development and pro-
gression of AKI [87]. An association between elevated 
central venous pressure, renal venous congestion and 
development of AKI, mainly reported in congestive heart 
failure, has also been found in other ICU patient cohorts 
[88, 89]. A randomized trial in ARDS patients found fluid 
restrictive strategies to be safe [90]. In contrast, peri-
operative restrictive fluid management increased the risk 
of AKI in patients undergoing major elective abdominal 
surgery [91]. In established AKI, the role of fluid restric-
tion remains uncertain and likely depends on pre-exist-
ing intravascular volume status. A pilot study in critically 
ill patients with AKI showed that restricting fluid intake 
with the aim to prevent fluid overload was associated a 
lower incidence of adverse effects and less need for RRT 
[92]. Similarly, a strategy of active fluid restriction after 
initial fluid resuscitation in patients with septic shock 
was associated with less AKI progression [93] but this 
finding could not be reproduced in two subsequent tri-
als using a similar approach [94, 95]. The results of ongo-
ing RCTs examining the effectiveness and safety of fluid 
restriction and the role of active de-resuscitation in high-
risk patients are awaited [96].
The type of crystalloid fluid for resuscitation has also 
been evaluated in recent large RCTs in non-critically ill 
and critically ill patients. The SMART study, which com-
pared saline with buffered crystalloids, showed a lower 
incidence of major adverse kidney events (MAKE) in 
those receiving buffered crystalloids, but there was no 
significant difference in maximum stage of AKI, need for 
RRT or proportion of patients with at least a doubling 
of Scr. There was also no difference in median volume 
of fluid between both groups. Among patients with sep-
sis, the use of buffered crystalloids was associated with a 
lower 30-day in-hospital mortality compared with use of 
saline [97].
Kidney perfusion pressure
Conditions with non-fluid-responsive impaired car-
diac output (CO) may require inotropes. Interestingly, 
the intervention arm of the PREV-AKI study, showing a 
beneficial effect of a care bundle, used more dobutamine 
[17]. With regards to early AKI, observational evidence 
suggests a higher CO and oxygen delivery (DO2) may be 
beneficial to prevent its progression [98], although early 
goal-direct therapy in general does not impact AKI [99]. 
It is important to note that AKI may also occur in situa-
tions of normal or increased kidney perfusion pressure 
due to development of intrarenal shunting and micro-
circulatory disturbances [50]. Every effort should be 
made to avoid severe hypotension, a definite cause for 
AKI, especially in  situations of disturbed autoregula-
tion. The ideal mean arterial pressure (MAP) to avoid 
AKI remains to be determined and might need to be 
tailored to patients’ characteristics [100]. In 2463 sepsis 
patients aged > 65 years, “permissive hypotension” (MAP 
60–65 mm Hg) was not associated with need for RRT or 
an increased 90-day mortality compared to usual care; 
less severe AKI was not assessed though [101]. On the 
other hand, in a RCT in septic shock patients, a lower 
MAP target was related to doubling of creatinine or need 
for RRT in the subgroup of patients with chronic hyper-
tension [102]. Similarly, maintaining systolic BP in the 
operating room within 10% of resting systolic BP resulted 
in a significantly lower incidence of postoperative AKI 
compared to a fixed (80 mmHg) target in high-risk adults 
undergoing major surgery [103]. A retrospective study of 
septic shock patients, stratified according to the differ-
ence between pre-morbid and post-resuscitation MAP, 
showed that the incidence of AKI was lowest among 
those whose post-resuscitation MAP was closest to or 
higher than their pre-morbid MAP [104]. Therefore, it 
appears plausible that a more personalized approach, 
mainly based on pre-existing values, may be the optimal 
way to manage blood pressure. In addition, more atten-
tion should be given to importance of renal perfusion 
pressure (MAP-CVP) [105, 106].
The impact of different vasoactive or inotropic medica-
tions on kidney function varies and may depend on the 
underlying condition. The most frequently used vaso-
pressor to maintain renal perfusion pressure is norepi-
nephrine [107]. The effects of phenylephrine, a pure α-1 
agonist, on renal function are poorly investigated, but 
without evidence for benefit [108]. Catecholamines may 
have side effects at higher doses. Vasopressin, an endog-
enous non-catecholamine vasopressor, has the ability to 
preferentially constrict efferent glomerular arterioles, 
thus increasing glomerular perfusion pressure and urine 
generation. While in the Vasopressin vs Norepineph-
rine as Initial Therapy in Septic Shock (VANISH) trial 
[109], the number of kidney failure-free days was simi-
lar in patients who received noradrenaline or vasopres-
sin, patients in the vasopressin group had lower Scr 
levels and higher urinary output in the first 7 days, lead-
ing to lower use of RRT (25.4% vs. 35.3%). A meta-analy-
sis including 4 RCTs concluded that vasopressin reduced 
the requirement for RRT (RR 0.86, 95% CI 0.74–0.99), 
but this finding was not robust to sensitivity analyses 
[110]. More recently, the Vasopressin versus Norepi-
nephrine in Patients with Vasoplegic Shock after Cardiac 
Surgery (VANCS) trial demonstrated a significantly bet-
ter primary composite outcome in patients randomized 
to vasopressin versus norepinephrine, an effect primar-
ily driven by a lower rate of AKI [111]. Angiotensin II 
infusion has recently been investigated in patients with 
shock demonstrating equal hemodynamic stabilization 
as achieved by norepinephrine (ATHOS-3, [112]). A post 
hoc analysis of this trial showed that in a subgroup of 
patients on RRT, duration of RRT was shorter and sur-
vival higher in patients who received angiotensin-II com-
pared to norepinephrine [113], a finding that warrants 
confirmation. Naturally, potential impact on kidney func-
tion should always be weighed against potential adverse 
effects.
Biomarkers to guide management
Several single-center studies in patients undergoing 
major surgery suggested that initiation of a KDIGO pre-
vention bundle in high-risk patients identified by bio-
markers could reduce the incidence and progression of 
AKI however, without beneficial effect on patient-cen-
tered outcome [17, 18]. Biomarker-guided management 
of nephrotoxic drugs has also been advocated as a form 
of nephrotoxin stewardship [114]. The strength of evi-
dence currently precludes the routine use of biomarkers 
to guide decision-making on when to initiate RRT [115]. 
New biomarkers of kidney non-recovery have been dis-
covered, i.e., CCL14 [39]. Their potential role in guiding 
RRT initiation needs to be determined in future studies. 
A study in 162 patients with AKI showed that the furo-
semide stress test (FST) had excellent predictive ability 
for subsequent use of RRT [116]. However, there was no 
difference in outcome between early versus standard ini-
tiation of RRT in FST non-responders.
New drugs
To date, there are no specific drugs or therapies that 
prevent or treat AKI. A recent multicenter RCT demon-
strated that human recombinant alkaline phosphatase 
(AP), an enzyme that dephosphorylates endotoxin and 
ATP, was not associated with a significant improve-
ment of endogenous creatinine clearance during the first 
7  days. However, creatinine clearance up to day 28 was 
better and all-cause mortality was lower [117]. Other 
promising agents include novel compounds, repurposed 
drugs and cell-based therapies targeting a variety of 
pathways, including mitochondrial stress, cell metabo-
lism, inflammation, antioxidant effects, apoptosis, repair 
mechanisms and systemic hemodynamics [118] (Supple-
mental Table 1). Some of these compounds are progress-
ing through early-phase clinical trials.
Initiation of RRT 
Four out of five recent RCTs [119–124] (Supplemental 
Table 2) failed to demonstrate a survival benefit of early 
RRT initiation, in patients without evident urgent indi-
cations. Concern exists about possible harm of early 
initiation (hypotension, hypophosphataemia, prolonged 
dialysis dependence) and a “watch and wait” strategy 
appears to be safe up to a certain point [125]. The recent 
AKIKI 2 trial compared ‘delayed’ with ‘very delayed’ ini-
tiation of RRT and demonstrated no difference in the 
number of RRT-free days between both groups [124] but 
60-day mortality was higher in the ‘very delayed’ arm. 
Robust evidence for biomarker-guided RRT initiation is 
lacking [114]. The role of furosemide stress test is still to 
be established. In some patients, a more individualized 
decision may be appropriate [59].
Long‑term outcome following AKI
Several retrospective studies, mostly based on admin-
istrative databases, have shown that AKI, even after 
apparent full recovery, is associated with unfavora-
ble long-term outcomes, including an increased risk of 
dying, occurrence of cardiovascular events and develop-
ment of (or progression to) CKD [2, 3]. These findings 
were recently confirmed in a prospective cohort (ASSESS 
study) including hospital survivors at 3  months with or 
without AKI during hospitalization with a median of 4.7-
year follow-up [126]. The increased risk of death appears 
to prevail over the risk of new CKD. Main causes of mor-
tality are cardiovascular events and cancer [3]. Besides 
the expected risk factors (e.g., age, comorbidities, AKI 
severity), the recovery pattern of AKI also appears to be 
associated with long-term mortality [127, 128].
Whether the association of AKI with long-term 
cardiovascular events is related to shared risk factors 
(diabetes, hypertension, heart failure, pre-existing 
CKD), the increased incidence of CKD (a known risk 
factor for cardiovascular disease [76]) or to a causal 
relationship has not been clearly established but evi-
dence is accumulating that AKI itself may accelerate 
cardiovascular disease [3, 129], likely related to AKI-
induced remote organ injury and systemic inflamma-
tion (organ cross-talk). The pathophysiology is likely 
multifactorial. Galectin-3, a substance that induces 
cardiac inflammation, cardiac fibrosis and cardiac 
dysfunction may contribute [83]. Activation of the 
RAAS after AKI has also been identified as a media-
tor of cardiovascular damage after AKI as Angiotensin 
II induces macrophage infiltration, cardiac inflam-
mation and myocardial fibrosis ultimately leading to 
cardiac dysfunction and heart failure [130]. The risk 
of incident and progressive CKD has been shown in 
retrospective and prospective studies [3, 126] and can 
contribute to poor long-term outcomes. AKI is a risk 
factor for subsequent proteinuria [131], an independ-
ent predictor of adverse outcomes [126]. Other risk 
factors for the AKI–CKD transition include duration 
and severity of  kidney  injury, older age and chronic 
health conditions, including baseline kidney func-
tion. The ASSESS study showed that patients with 
AKI lasting more than 72 h had a higher risk of CKD 
than those with resolving AKI and that proteinuria 
at 3  months was a strong predictor of further dete-
rioration of kidney function [132]. The mechanisms 
underlying the AKI–CKD transition are incompletely 
elucidated but thought to include maladaptive tubular 
repair, persistent microvascular damage and inflam-
mation leading to fibrosis [133].
The need for better follow-up and long-term care of 
patients recovering from AKI or AKD is increasingly 
being recognized. Several institutions and health care 
systems have developed AKI follow-up clinics [134]. 
However, there is also a need for specific quality indi-
cators and quality measures and better quantification 
of the impact of these organization on patient-centered 
outcomes [135]. Strategies to prevent long-term com-
plications of AKI have emerged recently. First, pre-
vention of new episodes of AKI (e.g., with avoidance 
of nephrotoxins) is important [64, 136]. Recognition 
and treatment of hypertension, diabetes, or obesity 
are potential key factors to improve long-term out-
comes. In this line, an observational study showed that 
follow-up by a nephrologist was associated with lower 
long-term all-cause mortality following AKI [137], but 
implementation in clinical practice would impose a 
substantial burden on the nephrology community. This 
calls for risk-stratified follow-up [138], driven by pro-
teinuria [129] and estimated GFR at discharge, poten-
tially aided by biomarker levels [11, 56, 139].
Several cardio- and renoprotective pharmacological 
strategies hold promise to improve post-AKI outcomes. 
Reducing the consequences of RAAS activation after 
AKI appears to improve long-term mortality in patients 
recovering from AKI [140]. Treatments with selective 
mineralocorticoid receptor antagonists or sodium-
glucose co-transporter-2 inhibitors have recently been 
shown to improve clinical outcomes (mortality or pro-
gression of CKD and cardiovascular events) in CKD 
patients [141, 142]. Whether these results translate into 
better post-AKI outcomes needs to be explored.
Conclusion
AKI is a heterogenous syndrome that may present in 
different phenotypes, not reflected in the current crite-
ria that define AKI. Novel developments including bio-
markers and machine learning hold promise to be more 
sensitive and predictive of the development of AKI. In 
addition, biomarker kinetics may reveal more insight 
into the pathogenesis as observed in the subclinical AKI 
groups identified. Nevertheless, clinical trials are needed 
to assess their real usefulness. If so, a more personalized 
approach, taking into account the underlying pathophysi-
ology, may change the way AKI is viewed and managed 
in the future. In those patients who may need RRT, more 
clinical data regarding timing of initiation are now avail-
able illustrating that a somewhat reserved approach is 
acceptable. In addition, it is becoming clear that, apart 
from short-term consequences of AKI, long-term seque-
lae may occur in AKI survivors and follow-up of this spe-
cific patient group warrants further attention.
Supplementary Information
The online version contains supplementary material available at https:// doi. 
org/ 10. 1007/ s00134- 021- 06454-7.
Author details
1 Department of Intensive Care, Radboud University Medical Centre, PO 
Box 9101, NL 6500 HB Nijmegen, The Netherlands. 2 APHP, Service de 
médecine intensive et de réanimation, Hôpital Saint-Louis, 1 avenue Claude 
Vellefaux, 75010 Paris, France. 3 Université de Paris, ECSTRA Team, UMR 1153, 
Center of Epidemiology and Biostatistics, INSERM, Paris, France. 4 Depart-
ment of Intensive Care Medicine, Ghent University Hospital, Ghent University, 
C. Heymanslaan 10, 9000 Ghent, Belgium. 5 Research Foundation—Flan-
ders (FWO), Egmontstraat 5, 1000 Brussels, Belgium. 6 Division of Intensive 
Care and Emergency Medicine, Department of Internal Medicine, Medical 
University of Innsbruck, Innsbruck, Austria. 7 Department of Anesthesia 
and Peri-Operative Care, Division of Critical Care Medicine, University of Cali-
fornia San Francisco, San Francisco, USA. 8 Department of Critical Care, King’s 
College London, Guy’s & St Thomas’ Hospital, London SE1 9RT, UK. 9 Adult 
Critical Care Unit, Department of Renal Medicine and Transplantation, The 
Royal London Hospital, Barts Health NHS Trust, London, UK. 10 William Harvey 
Research Institute, Queen Mary University of London, London, UK. 11 Adult 
Intensive Care Unit, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, 
Switzerland. 12 Clinical Department and Laboratory of Intensive Care Medicine, 
Division of Cellular and Molecular Medicine, KU Leuven University, Herestraat 





PP declares having received speaker fees from Baxter and consultancy fees 
from AM-Pharma. MD declares having received speaker fees from Astelas, 
Gilead-Kite and MSD along with a grant from MSD outside the scope of this 
manuscript. EH declares speaker fees from Alexion and Sopachem (paid to 
the university), travel grant from AM-Pharma. MJ has received honoraria and 
research support from Baxter Healthcare Corp, AM-Pharma, CLS Behring, 
Fresenius, and Astute Medical. ML declares no conflict of interest. MO declares 
speaker fees from Fresenius and Biomerieux, research funding from Baxter, 
Biomerieux and LaJolla Pharma and consultancy fee from NxStage. JRP has 
received grant and/or research support from bioMérieux, consulting fees from 
Medibeacon Inc., Beckton Dickinson Inc and Jafron Biomedical Co Ltd and 
speaker’s honoraria from Nikkiso Europe GmbH, Baxter, Braun Medical Ltd, 
Fresenius Medical Care and Fresenius-Kabi UK. AS has received a grant from 
the Leenaards foundation, speaker honoraria from Fresenius Medical Care 
and consulting honoraria from B Braun Melsungen AG. MS has no conflict of 
interest to declare.
Open Access
This article is licensed under a Creative Commons Attribution-NonCommercial 
4.0 International License, which permits any non-commercial use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as 
you give appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons licence, and indicate if changes were made. The 
images or other third party material in this article are included in the article’s 
Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence 
and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright 
holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen 
ses/ by- nc/4. 0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
Received: 2 March 2021   Accepted: 4 June 2021
References
 1. Disease K (2012) Improving global outcomes (KDIGO) acute kidney 
injury work group (2012) KDIGO clinical practice guidelines AKI: AKI 
definition. Kidney Int Supplements 2(1):19–36
 2. Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM 
et al (2018) Global epidemiology and outcomes of acute kidney injury. 
Nat Rev Nephrol 14(10):607–625
 3. James MT, Bhatt M, Pannu N, Tonelli M (2020) Long-term outcomes of 
acute kidney injury and strategies for improved care. Nat Rev Nephrol 
16(4):193–205
 4. Kellum JA, Prowle JR (2018) Paradigms of acute kidney injury in the 
intensive care setting. Nat Rev Nephrol 14(4):217–230
 5. Schetz M, Schortgen F (2017) Ten shortcomings of the current defini-
tion of AKI. Intensive Care Med 43(6):911–913
 6. Priyanka P, Zarbock A, Izawa J, Gleason TG, Renfurm RW, Kellum JA 
(2020) The impact of acute kidney injury by serum creatinine or urine 
output criteria on major adverse kidney events in cardiac surgery 
patients. J Thorac Cardiovasc Surg. https:// doi. org/ 10. 1016/j. jtcvs. 2019. 
11. 137
 7. Kellum JA, Sileanu FE, Murugan R, Lucko N, Shaw AD, Clermont G (2015) 
Classifying AKI by urine output versus serum creatinine level. J Am Soc 
Nephrol 26(9):2231–2238
 8. Ronco C, Bellomo R, Kellum J (2017) Understanding renal functional 
reserve. Intensive Care Med 43(6):917–920
 9. Chen S (2013) Retooling the creatinine clearance equation to estimate 
kinetic GFR when the plasma creatinine is changing acutely. J Am Soc 
Nephrol 24(6):877–888
 10. Schneider AG, Molitoris BA (2020) Real-time glomerular filtration rate: 
improving sensitivity, accuracy and prognostic value in acute kidney 
injury. Curr Opin Crit Care 26(6):549–555
 11. Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan 
R, et al. Recommendations on acute kidney injury biomarkers from 
the acute disease quality initiative consensus conference: a consensus 
statement. JAMA Netw Open. 2020;3(10):e2019209.
 12. Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M et al 
(2013) Discovery and validation of cell cycle arrest biomarkers in 
human acute kidney injury. Critical care (London, England) 17(1):R25
 13. Hoste EA, McCullough PA, Kashani K, Chawla LS, Joannidis M, Shaw AD 
et al (2014) Derivation and validation of cutoffs for clinical use of cell 
cycle arrest biomarkers. Nephrol Dial Transpl 29(11):2054–2061
 14. Su LJ, Li YM, Kellum JA, Peng ZY (2018) Predictive value of cell cycle 
arrest biomarkers for cardiac surgery-associated acute kidney injury: a 
meta-analysis. Br J Anaesth 121(2):350–357
 15. Zhang D, Yuan Y, Guo L, Wang Q (2019) Comparison of urinary TIMP-2 
and IGFBP7 cut-offs to predict acute kidney injury in critically ill 
patients: a PRISMA-compliant systematic review and meta-analysis. 
Medicine (Baltimore) 98(26):e16232
 16. Albert C, Zapf A, Haase M, Rover C, Pickering JW, Albert A, et al. (2020) 
Neutrophil gelatinase-associated lipocalin measured on clinical labora-
tory platforms for the prediction of acute kidney injury and the associ-
ated need for dialysis therapy: a systematic review and meta-analysis. 
Am J Kidney Dis 76(6):826–41 e1.
 17. Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J et al 
(2017) Prevention of cardiac surgery-associated AKI by implementing 
the KDIGO guidelines in high risk patients identified by biomark-
ers: the PrevAKI randomized controlled trial. Intensive Care Med 
43(11):1551–1561
 18. Göcze I, Jauch D, Götz M, Kennedy P, Jung B, Zeman F et al (2018) 
Biomarker-guided Intervention to prevent acute kidney injury after 
major surgery: the prospective randomized BigpAK study. Ann Surg 
267(6):1013–1020
 19. Husain-Syed F, Ferrari F, Sharma A, Danesi TH, Bezerra P, Lopez-
Giacoman S et al (2018) Preoperative renal functional reserve predicts 
risk of acute kidney injury after cardiac operation. Ann Thorac Surg 
105(4):1094–1101
 20. Husain-Syed F, Ferrari F, Sharma A, Hinna Danesi T, Bezerra P, Lopez-
Giacoman S et al (2019) Persistent decrease of renal functional reserve 
in patients after cardiac surgery-associated acute kidney injury despite 
clinical recovery. Nephrol Dialysis Transpl 34(2):308–317
 21. Hoste EA, Kashani K, Gibney N, Wilson FP, Ronco C, Goldstein SL et al 
(2016) Impact of electronic-alerting of acute kidney injury: workgroup 
statements from the 15(th) ADQI Consensus Conference. Can J Kidney 
Health Dis 3:10
 22. Al-Jaghbeer M, Dealmeida D, Bilderback A, Ambrosino R, Kellum JA 
(2018) Clinical decision support for in-hospital AKI. J Am Soc Nephrol 
29(2):654–660
 23. Colpaert K, Hoste EA, Steurbaut K, Benoit D, Van Hoecke S, De Turck 
F et al (2012) Impact of real-time electronic alerting of acute kidney 
injury on therapeutic intervention and progression of RIFLE class. Crit 
Care Med 40(4):1164–1170
 24. De Vlieger G, Kashani K, Meyfroidt G (2020) Artificial intelligence to 
guide management of acute kidney injury in the ICU: a narrative review. 
Curr Opin Crit Care 26(6):563–573
 25. Gameiro J, Branco T, Lopes JA (2020) Artificial intelligence in acute kid-
ney injury risk prediction. J Clin Med. 9(3):678. https:// doi. org/ 10. 3390/ 
jcm90 30678
 26. Flechet M, Guiza F, Schetz M, Wouters P, Vanhorebeek I, Derese I et al 
(2017) AKIpredictor, an online prognostic calculator for acute kidney 
injury in adult critically ill patients: development, validation and com-
parison to serum neutrophil gelatinase-associated lipocalin. Intensive 
Care Med 43(6):764–773
 27. Koyner JL, Carey KA, Edelson DP, Churpek MM (2018) The development 
of a machine learning inpatient acute kidney injury prediction model. 
Crit Care Med 46(7):1070–1077
 28. Chiofolo C, Chbat N, Ghosh E, Eshelman L, Kashani K (2019) Automated 
continuous acute kidney injury prediction and surveillance: a random 
forest model. Mayo Clin Proc 94(5):783–792
 29. Churpek MM, Carey KA, Edelson DP, Singh T, Astor BC, Gilbert ER et al 
(2020) Internal and external validation of a machine learning risk score 
for acute kidney injury. JAMA Netw Open 3(8):e2012892
 30. Chaudhary K, Vaid A, Duffy A, Paranjpe I, Jaladanki S, Paranjpe M 
et al (2020) Utilization of deep learning for subphenotype identifica-
tion in sepsis-associated acute kidney injury. Clin J Am Soc Nephrol 
15(11):1557–1565
 31. Wiersema R, Jukarainen S, Vaara ST, Poukkanen M, Lakkisto P, Wong 
H et al (2020) Two subphenotypes of septic acute kidney injury are 
associated with different 90-day mortality and renal recovery. Critical 
care (London, England) 24(1):150
 32. Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM 
et al (2017) Acute kidney disease and renal recovery: consensus report 
of the acute disease quality initiative (ADQI) 16 Workgroup. Nat Rev 
Nephrol 13(4):241–257
 33. Pons B, Lautrette A, Oziel J, Dellamonica J, Vermesch R, Ezingeard E 
et al (2013) Diagnostic accuracy of early urinary index changes in 
differentiating transient from persistent acute kidney injury in critically 
ill patients: multicenter cohort study. Critical care (London, England) 
17(2):R56
 34. Darmon M, Bourmaud A, Reynaud M, Rouleau S, Meziani F, Boivin A 
et al (2018) Performance of Doppler-based resistive index and semi-
quantitative renal perfusion in predicting persistent AKI: results of a 
prospective multicenter study. Intensive Care Med 44(11):1904–1913
 35. Coca SG, Nadkarni GN, Garg AX, Koyner J, Thiessen-Philbrook H, McAr-
thur E et al (2016) First post-operative urinary kidney injury biomarkers 
and association with the duration of AKI in the TRIBE-AKI Cohort. PLoS 
ONE 11(8):e0161098
 36. Meersch M, Schmidt C, Van Aken H, Martens S, Rossaint J, Singbartl K 
et al (2014) Urinary TIMP-2 and IGFBP7 as early biomarkers of acute 
kidney injury and renal recovery following cardiac surgery. PLoS ONE 
9(3):e93460
 37. Legrand M, Jacquemod A, Gayat E, Collet C, Giraudeaux V, Launay JM 
et al (2015) Failure of renal biomarkers to predict worsening renal func-
tion in high-risk patients presenting with oliguria. Intensive Care Med 
41(1):68–76
 38. Titeca-Beauport D, Daubin D, Van Vong L, Belliard G, Bruel C, Alaya 
S et al (2020) Urine cell cycle arrest biomarkers distinguish poorly 
between transient and persistent AKI in early septic shock: a prospec-
tive, multicenter study. Critical care (London, England) 24(1):280
 39. Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M et al 
(2020) Identification and validation of biomarkers of persistent acute 
kidney injury: the RUBY study. Intensive Care Med 46(5):943–953
 40. Dewitte A, Joannes-Boyau O, Sidobre C, Fleureau C, Bats ML, Derache 
P et al (2015) Kinetic eGFR and novel AKI biomarkers to predict renal 
recovery. Clin J Am Soc Nephrol 10(11):1900–1910
 41. Koyner JL, Davison DL, Brasha-Mitchell E, Chalikonda DM, Arthur JM, 
Shaw AD et al (2015) Furosemide stress test and biomarkers for the 
prediction of AKI severity. J Am Soc Nephrol 26(8):2023–2031
 42. Chen JJ, Chang CH, Huang YT, Kuo G (2020) Furosemide stress test 
as a predictive marker of acute kidney injury progression or renal 
replacement therapy: a systemic review and meta-analysis. Critical care 
(London, England) 24(1):202
 43. Barasch J, Zager R, Bonventre JV (2017) Acute kidney injury: a problem 
of definition. Lancet 389(10071):779–781
 44. Xu K, Rosenstiel P, Paragas N, Hinze C, Gao X, Huai Shen T et al (2017) 
Unique transcriptional programs identify subtypes of AKI. J Am Soc 
Nephrol 28(6):1729–1740
 45. Mar D, Gharib SA, Zager RA, Johnson A, Denisenko O, Bomsztyk K (2015) 
Heterogeneity of epigenetic changes at ischemia/reperfusion- and 
endotoxin-induced acute kidney injury genes. Kidney Int 88(4):734–744
 46. Garofalo AM, Lorente-Ros M, Goncalvez G, Carriedo D, Ballén-Barragán 
A, Villar-Fernández A et al (2019) Histopathological changes of organ 
dysfunction in sepsis. Intensive Care Med Exp 7(Suppl 1):45
 47. Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH et al 
(2018) Worsening renal function in patients with acute heart failure 
undergoing aggressive diuresis is not associated with tubular injury. 
Circulation 137(19):2016–2028
 48. Rao VS, Ahmad T, Brisco-Bacik MA, Bonventre JV, Wilson FP, Siew ED 
et al (2019) Renal effects of intensive volume removal in heart failure 
patients with preexisting worsening renal function. Circ Heart Fail 
2(6):e005552
 49. Yoshioka K, Matsue Y, Okumura T, Kida K, Oishi S, Akiyama E et al (2020) 
Impact of brain natriuretic peptide reduction on the worsening renal 
function in patients with acute heart failure. PLoS ONE 15(6):e0235493
 50. Peerapornratana S, Manrique-Caballero CL, Gómez H, Kellum 
JA (2019) Acute kidney injury from sepsis: current concepts, 
epidemiology, pathophysiology, prevention and treatment. Kidney Int 
96(5):1083–1099
 51. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J et al 
(2014) A unified theory of sepsis-induced acute kidney injury: inflam-
mation, microcirculatory dysfunction, bioenergetics, and the tubular 
cell adaptation to injury. Shock (Augusta, Ga) 41(1):3–11
 52. Radi ZA (2018) Immunopathogenesis of Acute Kidney Injury. Toxicol 
Pathol 46(8):930–943
 53. Poyan Mehr A, Tran MT, Ralto KM, Leaf DE, Washco V, Messmer J et al 
(2018) De novo NAD(+) biosynthetic impairment in acute kidney injury 
in humans. Nat Med 24(9):1351–1359
 54. Kellum JA, Chawla LS (2016) Cell-cycle arrest and acute kidney injury: 
the light and the dark sides. Nephrol Dial Transplant 31(1):16–22
 55. Hayek SS, Leaf DE, Samman Tahhan A, Raad M, Sharma S, Waikar SS et al 
(2020) Soluble urokinase receptor and acute kidney injury. N Engl J 
Med 382(5):416–426
 56. Schunk SJ, Zarbock A, Meersch M, Kullmar M, Kellum JA, Schmit D et al 
(2019) Association between urinary dickkopf-3, acute kidney injury, 
and subsequent loss of kidney function in patients undergoing cardiac 
surgery: an observational cohort study. Lancet (London, England) 
394(10197):488–496
 57. Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S et al 
(2019) Identification of acute kidney injury subphenotypes with differ-
ing molecular signatures and responses to vasopressin therapy. Am J 
Respir Crit Care Med 199(7):863–872
 58. Bhatraju PK, Cohen M, Nagao RJ, Morrell ED, Kosamo S, Chai XY et al 
(2020) Genetic variation implicates plasma angiopoietin-2 in the devel-
opment of acute kidney injury sub-phenotypes. BMC Nephrol 21(1):284
 59. Ostermann M, Bellomo R, Burdmann EA, Doi K, Endre ZH, Goldstein SL, 
et al. Controversies in acute kidney injury: conclusions from a Kidney 
Disease: Improving Global Outcomes (KDIGO) Conference. Kidney 
international. 2020;98(2):294–309.
 60. McDonald JS, McDonald RJ, Williamson EE, Kallmes DF, Kashani K (2017) 
Post-contrast acute kidney injury in intensive care unit patients: a 
propensity score-adjusted study. Intensive Care Med 43(6):774–784
 61. Hinson JS, Al Jalbout N, Ehmann MR, Klein EY (2019) Acute kidney 
injury following contrast media administration in the septic patient: a 
retrospective propensity-matched analysis. J Crit Care 51:111–116
 62. Miyamoto Y, Iwagami M, Aso S, Yasunaga H, Matsui H, Fushimi K et al 
(2019) Association between intravenous contrast media exposure 
and non-recovery from dialysis-requiring septic acute kidney injury: a 
nationwide observational study. Intensive Care Med 45(11):1570–1579
 63. Rouve E, Lakhal K, Salmon Gandonnière C, Jouan Y, Bodet-Contentin 
L, Ehrmann S (2018) Lack of impact of iodinated contrast media on 
kidney cell-cycle arrest biomarkers in critically ill patients. BMC Nephrol 
19(1):308
 64. Joannidis M, Druml W, Forni LG, Groeneveld ABJ, Honore PM, Hoste E 
et al (2017) Prevention of acute kidney injury and protection of renal 
function in the intensive care unit: update 2017: expert opinion of the 
working group on prevention, AKI section, European society of inten-
sive care medicine. Intensive Care Med 43(6):730–749
 65. Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ et al 
(2020) Use of intravenous iodinated contrast media in patients with kid-
ney disease: consensus statements from the american college of radiol-
ogy and the national kidney foundation. Radiology 294(3):660–668
 66. Timal RJ, Kooiman J, Sijpkens YWJ, de Vries JPM, Verberk-Jonkers I, 
Brulez HFH et al (2020) Effect of no prehydration vs sodium bicarbonate 
prehydration prior to contrast-enhanced computed tomography in the 
prevention of postcontrast acute kidney injury in adults with chronic 
kidney disease: the kompas randomized clinical trial. JAMA Intern Med 
180(4):533–541
 67. Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin SS et al 
(2018) Outcomes after angiography with sodium bicarbonate and 
acetylcysteine. N Engl J Med 378(7):603–614
 68. Arnaud FCS, Libório AB (2020) Attributable nephrotoxicity of van-
comycin in critically ill patients: a marginal structural model study. J 
Antimicrob Chemother 75(4):1031–1037
 69. Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S et al 
(2021) The monitoring of vancomycin: a systematic review and meta-
analyses of area under the concentration-time curve-guided dosing 
and trough-guided dosing. BMC Infect Dis 21(1):153
 70. Covert KL, Knoetze D, Cole M, Lewis P (2020) Vancomycin plus piperacil-
lin/tazobactam and acute kidney injury risk: a review of the literature. J 
Clin Pharm Ther 45(6):1253–1263
 71. Selby AR, Hall RG, 2nd. Utilizing the Patient Care Process to Mini-
mize the Risk of Vancomycin-Associated Nephrotoxicity. J Clin Med. 
2019;8(6).
 72. Picard W, Bazin F, Clouzeau B, Bui HN, Soulat M, Guilhon E et al (2014) 
Propensity-based study of aminoglycoside nephrotoxicity in patients 
with severe sepsis or septic shock. Antimicrob Agents Chemother 
58(12):7468–7474
 73. Wagenlehner F, Lucenteforte E, Pea F, Soriano A, Tavoschi L, Steele 
VR, et al. Systematic review on estimated rates of nephrotoxicity and 
neurotoxicity in patients treated with polymyxins. Clin Microbiol Infect. 
2021.
 74. Sisay M, Hagos B, Edessa D, Tadiwos Y, Mekuria AN (2021) Polymyxin-
induced nephrotoxicity and its predictors: a systematic review and 
meta-analysis of studies conducted using RIFLE criteria of acute kidney 
injury. Pharmacol Res 163:105328
 75. Joannidis M, Forni LG, Klein SJ, Honore PM, Kashani K, Ostermann M 
et al (2020) Lung-kidney interactions in critically ill patients: consensus 
report of the acute disease quality initiative (ADQI) 21 workgroup. 
Intensive Care Med 46(4):654–672
 76. Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL et al 
(2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, 
and treatment strategies: a scientific statement from the American 
heart association. Circulation 139(16):e840–e878
 77. Depret F, Prud’homme M, Legrand M (2017) A role of remote organs 
effect in acute kidney injury outcome. Nephron 137(4):273–276
 78. Lee SA, Cozzi M, Bush EL, Rabb H (2018) Distant organ dysfunction in 
acute kidney injury: a review. Am J Kidney Dis 72(6):846–856
 79. Singbartl K, Formeck CL, Kellum JA (2019) Kidney-immune system 
crosstalk in AKI. Semin Nephrol 39(1):96–106
 80. Thakar CV, Yared JP, Worley S, Cotman K, Paganini EP (2003) Renal 
dysfunction and serious infections after open-heart surgery. Kidney Int 
64(1):239–246
 81. Liaño F, Junco E, Pascual J, Madero R, Verde E (1998) The spectrum of 
acute renal failure in the intensive care unit compared with that seen 
in other settings. The madrid acute renal failure study group. Kidney Int 
Suppl 66:S16-24
 82. Woodrow G, Turney JH (1992) Cause of death in acute renal failure. 
Nephrol Dial Transpl 7(3):230–234
 83. Prud’homme M, Coutrot M, Michel T, Boutin L, Genest M, Poirier F 
et al (2019) Acute kidney injury induces remote cardiac damage and 
dysfunction through the galectin-3 pathway. JACC Basic Transl Sci 
4(6):717–732
 84. Hassoun HT, Lie ML, Grigoryev DN, Liu M, Tuder RM, Rabb H (2009) 
Kidney ischemia-reperfusion injury induces caspase-dependent pul-
monary apoptosis. Am J Physiol Renal Physiol 297(1):F125–F137
 85. Girling BJ, Channon SW, Haines RW, Prowle JR (2020) Acute kidney 
injury and adverse outcomes of critical illness: correlation or causation? 
Clin Kidney J 13(2):133–141
 86. Tanaka S, Okusa MD (2020) Crosstalk between the nervous system and 
the kidney. Kidney Int 97(3):466–476
 87. Ostermann M, Liu K, Kashani K (2019) Fluid management in acute 
kidney injury. Chest 156(3):594–603
 88. Gambardella I, Gaudino M, Ronco C, Lau C, Ivascu N, Girardi LN (2016) 
Congestive kidney failure in cardiac surgery: the relationship between 
central venous pressure and acute kidney injury. Interact Cardiovasc 
Thorac Surg 23(5):800–805
 89. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC et al 
(2013) Association between systemic hemodynamics and septic acute 
kidney injury in critically ill patients: a retrospective observational study. 
Crit Care 17(6):R278
 90. Wiedemann HP, Wheeler AP, Bernard GR, Thompson BT, Hayden D, 
deBoisblanc B et al (2006) Comparison of two fluid-management 
strategies in acute lung injury. N Engl J Med 354(24):2564–2575
 91. Myles PS, Bellomo R, Corcoran T, Forbes A, Peyton P, Story D et al (2018) 
Restrictive versus liberal fluid therapy for major abdominal surgery. N 
Engl J Med 378(24):2263–2274
 92. Vaara ST, Ostermann M, Bitker L, Schneider A, Poli E, Hoste E, et al. 
Restrictive fluid management versus usual care in acute kidney injury 
(REVERSE-AKI): a pilot randomized controlled feasibility trial. Intensive 
Care Med. 2021.
 93. Hjortrup PB, Haase N, Bundgaard H, Thomsen SL, Winding R, Pettilä V 
et al (2016) Restricting volumes of resuscitation fluid in adults with sep-
tic shock after initial management: the CLASSIC randomised, parallel-
group, multicentre feasibility trial. Intensive Care Med 42(11):1695–1705
 94. Macdonald SPJ, Keijzers G, Taylor DM, Kinnear F, Arendts G, Fatovich DM 
et al (2018) Restricted fluid resuscitation in suspected sepsis associated 
hypotension (REFRESH): a pilot randomised controlled trial. Intensive 
Care Med 44(12):2070–2078
 95. Corl KA, Prodromou M, Merchant RC, Gareen I, Marks S, Banerjee D 
et al (2019) The restrictive IV fluid trial in severe sepsis and septic shock 
(RIFTS): a randomized pilot study. Crit Care Med 47(7):951–959
 96. Agrinier N, Monnier A, Argaud L, Bemer M, Virion JM, Alleyrat C et al 
(2019) Effect of fluid balance control in critically ill patients: Design of 
the stepped wedge trial POINCARE-2. Contemp Clin Trials 83:109–116
 97. Brown RM, Wang L, Coston TD, Krishnan NI, Casey JD, Wanderer JP et al 
(2019) Balanced crystalloids versus saline in sepsis A secondary analysis 
of the SMART clinical trial. Am J Respir Crit Care Med 200(12):1487–1495
 98. Raimundo M, Crichton S, Syed Y, Martin JR, Beale R, Treacher D et al 
(2015) Low systemic oxygen delivery and bp and risk of progression of 
early AKI. Clin J Am Soc Nephrol 10(8):1340–1349
 99. Kellum JA, Chawla LS, Keener C, Singbartl K, Palevsky PM, Pike FL et al 
(2016) The effects of alternative resuscitation strategies on acute 
kidney injury in patients with septic shock. Am J Respir Crit Care Med 
193(3):281–287
 100. Asfar P, Radermacher P, Ostermann M (2018) MAP of 65: target of the 
past? Intensive Care Med 44(9):1551–1552
 101. Lamontagne F, Richards-Belle A, Thomas K, Harrison DA, Sadique MZ, 
Grieve RD et al (2020) Effect of reduced exposure to vasopressors on 
90-day mortality in older critically Ill patients with vasodilatory hypo-
tension: a randomized clinical trial. JAMA 323(10):938–949
 102. Asfar P, Meziani F, Hamel JF, Grelon F, Megarbane B, Anguel N et al 
(2014) High versus low blood-pressure target in patients with septic 
shock. N Engl J Med 370(17):1583–1593
 103. Futier E, Lefrant JY, Guinot PG, Godet T, Lorne E, Cuvillon P et al (2017) 
Effect of individualized vs standard blood pressure management 
strategies on postoperative organ dysfunction among high-risk 
patients undergoing major surgery: a randomized clinical trial. JAMA 
318(14):1346–1357
 104. Moman RN, Ostby SA, Akhoundi A, Kashyap R, Kashani K (2018) Impact 
of individualized target mean arterial pressure for septic shock resusci-
tation on the incidence of acute kidney injury: a retrospective cohort 
study. Ann Intensive Care 8(1):124
 105. Ostermann M, Hall A, Crichton S (2017) Low mean perfusion pressure 
is a risk factor for progression of acute kidney injury in critically ill 
patients—a retrospective analysis. BMC Nephrol 18(1):151
 106. Wong BT, Chan MJ, Glassford NJ, Martensson J, Bion V, Chai SY et al 
(2015) Mean arterial pressure and mean perfusion pressure deficit in 
septic acute kidney injury. J Crit Care 30(5):975–981
 107. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R 
et al (2017) Surviving sepsis campaign: international guidelines for 
management of sepsis and septic shock: 2016. Intensive Care Med 
43(3):304–377
 108. Morelli A, Ertmer C, Rehberg S, Lange M, Orecchioni A, Laderchi A et al 
(2008) Phenylephrine versus norepinephrine for initial hemodynamic 
support of patients with septic shock: a randomized, controlled trial. 
Crit Care 12(6):R143
 109. Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, 
Cepkova M et al (2016) Effect of early vasopressin vs norepinephrine 
on kidney failure in patients with septic shock: the VANISH randomized 
clinical trial. JAMA 316(5):509–518
 110. Nagendran M, Russell JA, Walley KR, Brett SJ, Perkins GD, Hajjar L 
et al (2019) Vasopressin in septic shock: an individual patient data 
meta-analysis of randomised controlled trials. Intensive Care Med 
45(6):844–855
 111. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, 
Osawa EA et al (2017) Vasopressin versus norepinephrine in patients 
with vasoplegic shock after cardiac surgery: the VANCS randomized 
controlled trial. Anesthesiology 126(1):85–93
 112. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) 
Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 
377(5):419–430
 113. Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR 
et al (2018) Outcomes in patients with vasodilatory shock and renal 
replacement therapy treated with intravenous angiotensin II. Crit Care 
Med 46(6):949–957
 114. Kane-Gill SL, Meersch M, Bell M (2020) Biomarker-guided management 
of acute kidney injury. Curr Opin Crit Care 26(6):556–562
 115. Klein SJ, Brandtner AK, Lehner GF, Ulmer H, Bagshaw SM, Wiedermann 
CJ et al (2018) Biomarkers for prediction of renal replacement therapy 
in acute kidney injury: a systematic review and meta-analysis. Intensive 
Care Med 44(3):323–336
 116. Lumlertgul N, Peerapornratana S, Trakarnvanich T, Pongsittisak W, Sura-
sit K, Chuasuwan A et al (2018) Early versus standard initiation of renal 
replacement therapy in furosemide stress test non-responsive acute 
kidney injury patients (the FST trial). Critical care (London, England) 
22(1):101
 117. Pickkers P, Mehta RL, Murray PT, Joannidis M, Molitoris BA, Kellum JA 
et al (2018) Effect of human recombinant alkaline phosphatase on 
7-day creatinine clearance in patients with sepsis-associated acute 
kidney injury: a randomized clinical trial. JAMA 320(19):1998–2009
 118. Côté JM, Murray PT, Rosner MH (2020) New drugs for acute kidney 
injury. Curr Opin Crit Care 26(6):525–535
 119. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstädt 
H et al (2016) Effect of early vs delayed initiation of renal replacement 
therapy on mortality in critically ill patients with acute kidney injury: the 
ELAIN randomized clinical trial. JAMA 315(20):2190–2199
 120. Bagshaw SM, Wald R, Adhikari NKJ, Bellomo R, da Costa BR, Dreyfuss D 
et al (2020) Timing of initiation of renal-replacement therapy in acute 
kidney injury. N Engl J Med 383(3):240–251
 121. Gaudry S, Hajage D, Benichou N, Chaïbi K, Barbar S, Zarbock A et al 
(2020) Delayed versus early initiation of renal replacement therapy 
for severe acute kidney injury: a systematic review and individual 
patient data meta-analysis of randomised clinical trials. Lancet 
395(10235):1506–1515
 122. Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E 
et al (2016) Initiation strategies for renal-replacement therapy in the 
intensive care unit. N Engl J Med 375(2):122–133
 123. Barbar SD, Clere-Jehl R, Bourredjem A, Hernu R, Montini F, Bruyere R 
et al (2018) Timing of renal-replacement therapy in patients with acute 
kidney injury and sepsis. N Engl J Med 379(15):1431–1442
 124. Gaudry S, Hajage D, Martin-Lefevre L, Lebbah S, Louis G, Moschietto S 
et al (2021) Comparison of two delayed strategies for renal replacement 
therapy initiation for severe acute kidney injury (AKIKI 2): a multicentre, 
open-label, randomised, controlled trial. Lancet (London, England) 
397(10281):1293–1300
 125. Ostermann M, Lumlertgul N (2021) Wait and see for acute dialysis: but 
for how long? Lancet (London, England) 397(10281):1241–1243
 126. Ikizler TA, Parikh CR, Himmelfarb J, Chinchilli VM, Liu KD, Coca SG et al 
(2021) A prospective cohort study of acute kidney injury and kidney 
outcomes, cardiovascular events, and death. Kidney Int 99(2):456–465
 127. Bhatraju PK, Zelnick LR, Chinchilli VM, Moledina DG, Coca SG, Parikh CR 
et al (2020) Association between early recovery of kidney function after 
acute kidney injury and long-term clinical outcomes. JAMA Netw Open 
3(4):e202682
 128. Fiorentino M, Tohme FA, Wang S, Murugan R, Angus DC, Kellum JA 
(2018) Long-term survival in patients with septic acute kidney injury is 
strongly influenced by renal recovery. PLoS ONE 13(6):e0198269
 129. Bansal N, Matheny ME, Greevy RA Jr, Eden SK, Perkins AM, Parr SK et al 
(2018) Acute kidney injury and risk of incident heart failure among US 
veterans. Am J Kidney Dis 71(2):236–245
 130. Mehta RL, Rabb H, Shaw AD, Singbartl K, Ronco C, McCullough PA et al 
(2013) Cardiorenal syndrome type 5: clinical presentation, pathophysi-
ology and management strategies from the eleventh consensus con-
ference of the Acute dialysis quality initiative (ADQI). Contrib Nephrol 
182:174–194
 131. Parr SK, Matheny ME, Abdel-Kader K, Greevy RA Jr, Bian A, Fly J et al 
(2018) Acute kidney injury is a risk factor for subsequent proteinuria. 
Kidney Int 93(2):460–469
 132. Hsu CY, Chinchilli VM, Coca S, Devarajan P, Ghahramani N, Go AS et al 
(2020) Post-acute kidney injury proteinuria and subsequent kidney 
disease progression: the assessment, serial evaluation, and subsequent 
sequelae in acute kidney injury (ASSESS-AKI) study. JAMA Intern Med 
180(3):402–410
 133. Ferenbach DA, Bonventre JV (2015) Mechanisms of maladaptive repair 
after AKI leading to accelerated kidney ageing and CKD. Nat Rev Neph-
rol 11(5):264–276
 134. Silver SA, Goldstein SL, Harel Z, Harvey A, Rompies EJ, Adhikari NK et al 
(2015) Ambulatory care after acute kidney injury: an opportunity to 
improve patient outcomes. Can J Kidney Health Dis 2:36
 135. Liu KD, Forni LG, Heung M, Wu VC, Kellum JA, Mehta RL et al (2020) 
Quality of care for acute kidney disease: current knowledge gaps and 
future directions. Kidney Int Rep 5(10):1634–1642
 136. Kashani K, Rosner MH, Haase M, Lewington AJP, O’Donoghue DJ, Wilson 
FP et al (2019) Quality improvement goals for acute kidney injury. Clin J 
Am Soc Nephrol 14(6):941–953
 137. Harel Z, Wald R, Bargman JM, Mamdani M, Etchells E, Garg AX et al 
(2013) Nephrologist follow-up improves all-cause mortality of severe 
acute kidney injury survivors. Kidney Int 83(5):901–908
 138. James MT, Pannu N, Hemmelgarn BR, Austin PC, Tan Z, McArthur E 
et al (2017) Derivation and external validation of prediction models for 
advanced chronic kidney disease following acute kidney injury. JAMA 
318(18):1787–1797
 139. Puthumana J, Thiessen-Philbrook H, Xu L, Coca SG, Garg AX, Himmel-
farb J, et al. (2021) Biomarkers of inflammation and repair in kidney 
disease progression. J Clin Invest 131(3).
 140. Gayat E, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Jaber S et al 
(2018) Impact of angiotensin-converting enzyme inhibitors or receptor 
blockers on post-ICU discharge outcome in patients with acute kidney 
injury. Intensive Care Med 44(5):598–605
 141. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene 
T, Hou FF et al (2020) Dapagliflozin in patients with chronic kidney 
disease. N Engl J Med 383(15):1436–1446
 142. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P et al (2020) 
Effect of finerenone on chronic kidney disease outcomes in type 2 
diabetes. N Engl J Med 383(23):2219–2229
 143. Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z (2015) Diagnostic value 
of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble 
triggering receptor expressed on myeloid cells-1 in critically ill patients 
with sepsis-associated acute kidney injury. Critical care (London, Eng-
land) 19:223
 144. Delanaye P, Cavalier E, Morel J, Mehdi M, Maillard N, Claisse G et al 
(2014) Detection of decreased glomerular filtration rate in intensive 
care units: serum cystatin C versus serum creatinine. BMC Nephrol 15:9
 145. Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen 
O et al (2004) Early detection of acute renal failure by serum cystatin C. 
Kidney Int 66(3):1115–1122
 146. Khorashadi M, Beunders R, Pickkers P, Legrand M (2020) Proenkephalin: 
a new biomarker for glomerular filtration rate and acute kidney injury. 
Nephron 144(12):655–661
 147. Martensson J, Bellomo R (2014) The rise and fall of NGAL in acute 
kidney injury. Blood Purif 37(4):304–310
 148. Glassford NJ, Schneider AG, Xu S, Eastwood GM, Young H, Peck L et al 
(2013) The nature and discriminatory value of urinary neutrophil 
gelatinase-associated lipocalin in critically ill patients at risk of acute 
kidney injury. Intensive Care Med 39(10):1714–1724
 149. Geng J, Qiu Y, Qin Z, Su B (2021) The value of kidney injury molecule 1 
in predicting acute kidney injury in adult patients: a systematic review 
and Bayesian meta-analysis. J Transl Med 19(1):105
 150. Koyner JL, Garg AX, Shlipak MG, Patel UD, Sint K, Hong K et al (2013) 
Urinary cystatin C and acute kidney injury after cardiac surgery. Am J 
Kidney Dis 61(5):730–738
 151. Faubel S (2020) SuPAR: a potential predictive biomarker for acute 
kidney injury. Nat Rev Nephrol 16(7):375–376
 152. Lin X, Yuan J, Zhao Y, Zha Y (2015) Urine interleukin-18 in prediction 
of acute kidney injury: a systemic review and meta-analysis. J Nephrol 
28(1):7–16
 153. Xu Y, Xie Y, Shao X, Ni Z, Mou S (2015) L-FABP: a novel biomarker of 
kidney disease. Clin Chim Acta 445:85–90
 154. De Loor J, Herck I, Francois K, Van Wesemael A, Nuytinck L, Meyer E et al 
(2017) Diagnosis of cardiac surgery-associated acute kidney injury: 
differential roles of creatinine, chitinase 3-like protein 1 and neutrophil 
gelatinase-associated lipocalin: a prospective cohort study. Ann Inten-
sive Care 7(1):24
 155. Hoste EA, Vaara ST, De Loor J, Haapio M, Nuytinck L, Demeyere K et al 
(2020) Urinary cell cycle arrest biomarkers and chitinase 3-like protein 
1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc 
laboratory analysis on the FINNAKI cohort. Critical care (London, Eng-
land) 24(1):144
 156. Zarbock A, Kellum JA, Schmidt C, Van Aken H, Wempe C, Pavenstadt 
H et al (2016) Effect of early vs delayed initiation of renal replacement 
therapy on mortality in critically ill patients with acute kidney injury: the 
elain randomized clinical trial. JAMA 315(20):2190–2199
